Leveraging the Treg-intrinsic CTLA4–PKCη signaling pathway for cancer immunotherapy
Guardado en:
Autores principales: | Hsin-Yu Liu, Christophe Pedros, Kok-Fai Kong, Ann J Canonigo-Balancio, Wen Xue, Amnon Altman |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6b0727518baf4f5588b97fc3c4c8adbd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Molecular insight into isoform specific inhibition of PI3K-α and PKC-η with dietary agents through an ensemble pharmacophore and docking studies
por: Baki Vijaya Bhaskar, et al.
Publicado: (2021) -
Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy
por: Clayton Hardman, et al.
Publicado: (2020) -
Sublingual immunotherapy increases Treg/Th17 ratio in allergic rhinitis
por: Wang Jiarong, et al.
Publicado: (2021) -
Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas
por: Zohreh Amoozgar, et al.
Publicado: (2021) -
Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum CTLA-4 and IL-10.
por: Anna Maria Riccio, et al.
Publicado: (2012)